Analysis of liquid biopsies to improve diagnosis and follow-up in cancer and other conditions

Multi-omics analyses of liquid biopsies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN35928837

Enrollment

10000

Registered

2025-06-06

Start date

2016-11-15

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, risk of cancer and other somatic conditions Cancer

Interventions

The collection and analysis of liquid biopsies using various methods, mostly based on cfDNA, but also with multi-omics approaches. Comparison to diagnosis and follow-up performed within routine clinic

Eligibility

Sex/Gender

All

Age

0 Days to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cancer of a type included in the study 2. Individuals with a predisposition for cancer 3. Individuals with other somatic conditions not classified as cancer 4. Not able to give informed consent

Exclusion criteria

Exclusion criteria: Not meeting the participant exclusion criteria

Design outcomes

Primary

Measure	Time frame
Additional diagnostic or prognostic information provided by liquid biopsies measured using massive parallel sequencing, methylation analysis or targeted digital PCR at diagnosis	—

Secondary

Measure	Time frame
Prognostic information and correlation to survival from liquid biopsies measured using massive parallel sequencing, epigenetic analysis, targeted digital PCR and/or proteomics at diagnosis, during or after treatment or during follow-up	—

Countries

Sweden

Contacts

Public ContactEmma Tham

emma.tham@ki.se+46-12370000

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026